4EBP-Activating Agents for Seizure Control in mTOR Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodevelopmental disorders involving mTOR hyperactivity, such as focal cortical dysplasia type II and tuberous sclerosis complex, are either invasive or associated with serious adverse events and are not fully effective in preventing seizures, which are experienced by nearly all patients, leading to significant neurocognitive and psychological disabilities.
Innovation Solution
A method involving the use of a 4EBP-activating agent or an EIF4E-depleting agent, delivered via viral vectors, to target and modify the activity of cells in the brain, specifically neurons with focal cortical malformations, to prevent seizures by normalizing cap-dependent translation and reducing mTOR hyperactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical resection or anti-epileptic drugs are used to treat seizures in mTOR disorders, then seizure control is attempted, but the treatments are either invasive or associated with serious adverse events and are not fully effective
Solution Approach 1:
The invention changes the molecular parameters of translation regulation by modulating 4EBP1 activity and eIF4E availability, thereby normalizing cap-dependent translation in mTOR hyperactive states without requiring surgical intervention or conventional anti-epileptic drugs, thus avoiding their associated harms while achieving seizure control
Solution Approach 2:
The invention uses 4EBP1 and eIF4E as intermediary targets to indirectly regulate mTOR pathway effects on translation, providing a more selective therapeutic approach that addresses the downstream consequences of mTOR hyperactivity without directly inhibiting mTOR, thereby reducing off-target adverse events
2Reliability
If conventional treatments are used for mTOR-related epilepsy, then some seizure management is achieved, but nearly two-thirds of patients remain refractory and experience life-long seizures
Solution Approach 1:
The invention changes the therapeutic parameter from broad mTOR inhibition or general anti-epileptic action to specific modulation of cap-dependent translation machinery (4EBP1-eIF4E axis), thereby achieving effective seizure prevention in previously refractory patients and improving long-term quality of life
Solution Approach 2:
The invention addresses the underlying translational dysregulation caused by mTOR hyperactivity before it leads to intractable epilepsy, by normalizing 4EBP1-mediated translation control, thereby preventing seizure development rather than merely managing symptoms
Data Source
AI summary
In various aspects and embodiments the invention provides a method of preventing seizures in a subject in need thereof, the method comprising contacting a target cell of the subject with a 4EBP-activating agent or a EIF4E-depleting agent.